newsfilter
← Latest News
GlobeNewswire·

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab (Erbitux) The